Article: Consumer Groups File Brief to Prevent Withdrawal of Generic BuSpar(R), According to Stop Patient Abuse Now; 50 Groups in 19 States Ask Court to Stop Bristol-Myers Squibb Effort.

WASHINGTON -- Fifty members of the Stop Patient Abuse Now coalition today submitted a brief to a federal court of appeals to support the right of drug makers to continue marketing generic versions of the anxiety drug BuSpar.

An appeals court ruled in October that a lower court should not have ordered the de-listing of a patent Bristol-Myers Squibb used to prevent sales of generic BuSpar. The court ruled that, despite a lower court's finding that the patent was frivolous and unlawfully listed, a generic drug manufacturer that requested the de-listing did not have proper legal standing to initiate the court action. The new ruling may allow Bristol to demand that ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!